Li A - Search Results

1

No causal effects between rosiglitazone and cardiovascular disease or risk factors: a Mendelian randomization study.

Li XM, Wu ZJ, Xu ZL, Li A, Liu MQ, Song CG, Wu K. Li XM, et al. Among authors: li a. Eur Rev Med Pharmacol Sci. 2023 Jun;27(11):5280-5292. doi: 10.26355/eurrev_202306_32647. Eur Rev Med Pharmacol Sci. 2023. PMID: 37318502 Free article.

2

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma.

Qin S, Yi M, Jiao D, Li A, Wu K. Qin S, et al. Among authors: li a. J Cancer. 2020 Jan 1;11(1):153-167. doi: 10.7150/jca.34693. eCollection 2020. J Cancer. 2020. PMID: 31892982 Free PMC article.

3

The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017.

Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. Yi M, et al. Among authors: li a. J Hematol Oncol. 2020 Jun 8;13(1):72. doi: 10.1186/s13045-020-00908-z. J Hematol Oncol. 2020. PMID: 32513227 Free PMC article.

4

Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017.

Yi M, Zhou L, Li A, Luo S, Wu K. Yi M, et al. Among authors: li a. Aging (Albany NY). 2020 Nov 16;12(22):22869-22891. doi: 10.18632/aging.103982. Epub 2020 Nov 16. Aging (Albany NY). 2020. PMID: 33203796 Free PMC article.

5

Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment.

Liu Q, Yu S, Li A, Xu H, Han X, Wu K. Liu Q, et al. Among authors: li a. Tumour Biol. 2017 Jun;39(6):1010428317712445. doi: 10.1177/1010428317712445. Tumour Biol. 2017. PMID: 28639898 Free article. Review.

6

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.

Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Qin S, et al. Among authors: li a. J Hematol Oncol. 2019 Mar 12;12(1):27. doi: 10.1186/s13045-019-0718-5. J Hematol Oncol. 2019. PMID: 30866992 Free PMC article. Review.

7

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.

Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Yi M, et al. Among authors: li a. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419876351. doi: 10.1177/1534735419876351. Integr Cancer Ther. 2019. PMID: 31517538 Free PMC article. Review.

8

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer.

Yu S, Yi M, Xu L, Qin S, Li A, Wu K. Yu S, et al. Among authors: li a. Front Oncol. 2020 Jan 10;9:1515. doi: 10.3389/fonc.2019.01515. eCollection 2019. Front Oncol. 2020. PMID: 31998654 Free PMC article.

9

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.

Yi M, Li A, Zhou L, Chu Q, Luo S, Wu K. Yi M, et al. Among authors: li a. Cancer Immunol Immunother. 2021 Jun;70(6):1705-1719. doi: 10.1007/s00262-020-02817-z. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33386920 Free PMC article.

10

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Yi M, et al. Among authors: li a. Mol Cancer. 2019 Mar 30;18(1):60. doi: 10.1186/s12943-019-0974-6. Mol Cancer. 2019. PMID: 30925919 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,352 results

Search Page

Filters